Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;106(1):26-32.
doi: 10.5935/abc.20150147. Epub 2015 Dec 22.

Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry

[Article in English, Portuguese]
Cristiano Guedes Bezerra  1 , Eduardo Leal Adam  1 , Mariana Lins Baptista  1 , Giuliano Serafino Ciambelli  1 , Liliane Kopel  1 , Claudia Bernoche  1 , Leonardo Nicolau Geisler Daud Lopes  1 , Milena Frota Macatrão-Costa  1 , Breno de Alencar Araripe Falcão  1 , Silvia Gelas Lage  1
Affiliations

Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry

[Article in English, Portuguese]
Cristiano Guedes Bezerra et al. Arq Bras Cardiol. 2016 Jan.

Abstract

Background: The use of aortic counterpulsation therapy in advanced heart failure is controversial.

Objectives: To evaluate the hemodynamic and metabolic effects of intra-aortic balloon pump (IABP) and its impact on 30-day mortality in patients with heart failure.

Methods: Historical prospective, unicentric study to evaluate all patients treated with IABP between August/2008 and July/2013, included in an institutional registry named TBRIDGE (The Brazilian Registry of Intra-aortic balloon pump in Decompensated heart failure - Global Evaluation). We analyzed changes in oxygen central venous saturation (ScvO2), arterial lactate, and use of vasoactive drugs at 48 hours after IABP insertion. The 30-day mortality was estimated by the Kaplan-Meier method and differences in subgroups were evaluated by the Log-rank test.

Results: A total of 223 patients (mean age 49 ± 14 years) were included. Mean left ventricle ejection fraction was 24 ± 10%, and 30% of patients had Chagas disease. Compared with pre-IABP insertion, we observed an increase in ScvO2 (50.5% vs. 65.5%, p < 0.001) and use of nitroprusside (33.6% vs. 47.5%, p < 0.001), and a decrease in lactate levels (31.4 vs. 16.7 mg/dL, p < 0.001) and use of vasopressors (36.3% vs. 25.6%, p = 0.003) after IABP insertion. Thirty-day survival was 69%, with lower mortality in Chagas disease patients compared without the disease (p = 0.008).

Conclusion: After 48 hours of use, IABP promoted changes in the use of vasoactive drugs, improved tissue perfusion. Chagas etiology was associated with lower 30-day mortality. Aortic counterpulsation therapy is an effective method of circulatory support for patients waiting for heart transplantation.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Thirty-day survival curve.
Figure 2
Figure 2
Comparison of 30-day mortality between transplant patients (with Tx) and non-transplant patients (without Tx). n: number of patients at risk; 95%CI: 95% confidence interval. P-value was calculated using the Log-rank test: p < 0.001.
Figure 3
Figure 3
Comparison of 30-day mortality between patients with Chagas disease and other cardiomyopathies. n: number of patients at risk; 95% CI: 95% confidence interval. p value was calculated using the Log-rank test: p = 0.008.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sanborn TA, Sleeper LA, Bates EE, Jacobs AK, Boland J, French JK, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36(3) Suppl A:1123–1129. - PubMed
    1. Ferguson JJ, 3rd, Cohen M, Freedman RJ, Jr, Stone GW, Miller MF, Joseph DL, et al. The current practice of intra-aortic balloon counterpulsation: results from Benchmark Registry. J Am Coll Cardiol. 2001;38(5):1456–1462. - PubMed
    1. Stone GW, Ohman EM, Miller MF, Joseph DL, Christenson JT, Cohen M, et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol. 2003;41(11):1940–1945. - PubMed
    1. Cohen M, Urban P, Christenson JT, Joseph DL, Freedman RJ, Jr, Miller MF, et al. Benchmark Registry Collaborators Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry. Eur Heart J. 2003;24(19):1763–1770. - PubMed
    1. Santa-Cruz RA, Cohen MG, Ohman EM. Aortic counterpulsation: a review of the hemodynamic effects and indications for use. Catheter Cardiovasc Interv. 2006;67(1):68–77. - PubMed

Publication types

MeSH terms